BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35133477)

  • 1. Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.
    Gagné M; Lauzier S; Lemay M; Loiselle CG; Provencher L; Simard C; Guillaumie L
    Support Care Cancer; 2022 Jun; 30(6):4759-4768. PubMed ID: 35133477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach.
    Labonté M; Guillaumie L; Dionne A; Dorval M; Nabi H; Lemieux J; Provencher L; Lauzier S
    Res Social Adm Pharm; 2020 Dec; 16(12):1724-1736. PubMed ID: 32205070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
    Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
    Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the HT&Me intervention to support women with breast cancer to adhere to adjuvant endocrine therapy and improve quality of life.
    Stewart SF; Slodkowska-Barabasz J; McGeagh L; Moon Z; Brett J; Wells M; Brown MC; Turner M; Horne R; Fenlon D; Rehman F; Cain H; Donnelly P; Harmer V; Turner L; Rose J; Sharp L; Watson E;
    Breast; 2023 Aug; 70():32-40. PubMed ID: 37300986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
    Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
    Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy.
    Green SMC; French DP; Graham CD; Hall LH; Rousseau N; Foy R; Clark J; Parbutt C; Raine E; Gardner B; Velikova G; Moore SJL; Buxton J; ; Smith SG
    BMC Health Serv Res; 2022 Aug; 22(1):1081. PubMed ID: 36002831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.
    Toivonen KI; Oberoi D; King-Shier K; Piedalue KL; Rash JA; Carlson LE; Campbell TS
    Curr Oncol; 2021 Jul; 28(4):2496-2515. PubMed ID: 34287250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Controlled Pilot Trial of a Low-Touch Remotely-Delivered Values Intervention to Promote Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors.
    Arch JJ; Crespi CM; Levin ME; Genung SR; Nealis M; Mitchell JL; Bright EE; Albright K; Magidson JF; Stanton AL
    Ann Behav Med; 2022 Aug; 56(8):856-871. PubMed ID: 35323853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
    En-Nasery-de Heer S; Tromp VNMF; Westerman MJ; Konings I; Beckeringh JJ; Boons CLM; Timmers L; Hugtenburg JG
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13749. PubMed ID: 36300863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
    Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment.
    Green SMC; Hall LH; French DP; Rousseau N; Parbutt C; Walwyn R; Smith SG
    Ann Behav Med; 2023 Oct; 57(11):988-1000. PubMed ID: 37494669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Adjuvant Endocrine Therapy Among Post-Menopausal Breast Cancer Patients in Malaysia.
    Saiful Bahri A; Tuan Mahmood TM; Abdul-Aziz SA; Makmor-Bakry M; Mohamed Shah N
    Patient Prefer Adherence; 2021; 15():227-235. PubMed ID: 33568899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions.
    Humphries B; Collins S; Guillaumie L; Lemieux J; Dionne A; Provencher L; Moisan J; Lauzier S
    Pharmacy (Basel); 2018 Jun; 6(2):. PubMed ID: 29890738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying the theory of planned behavior to examine adjuvant endocrine therapy adherence intentions.
    Hurtado-de-Mendoza A; Carrera P; Parrott WG; Gómez-Trillos S; Perera RA; Sheppard VB
    Psychooncology; 2019 Jan; 28(1):187-194. PubMed ID: 30353610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.